Understanding precisely how ultra-processed foods (UPFs) damage the cardiovascular system has long been the missing mechanistic link in an otherwise well-established epidemiological story. A multi-cohort metabolomics investigation now maps, at the molecular level, the biological footprint that UPF consumption leaves in the bloodstream — and connects that footprint directly to coronary heart disease, cardiovascular mortality, and total mortality.
Working across three large U.S. prospective cohorts totaling more than 7,600 participants — the Southern Community Cohort Study, the PLCO Cancer Screening Trial, and the Atherosclerosis Risk in Communities Study — researchers screened approximately 1,100 circulating metabolites using untargeted blood metabolomics. UPF intake was classified by the NOVA system and quantified via food frequency questionnaires at cohort baseline. A two-stage discovery-and-validation design identified 142 candidate metabolites in the discovery cohort, of which 43 were independently validated across the two replication cohorts. A composite metabolite signature (MetSig) derived from these markers was then prospectively associated with incident coronary heart disease, cardiovascular death, and all-cause mortality using Cox and conditional logistic regression models, with false discovery rate controlled at less than 10%.
This work is notable for several reasons beyond its sample size. Untargeted metabolomics is an agnostic approach — it does not presume which biological pathways matter — making validated hits more credible than hypothesis-driven screens. The three-cohort replication architecture is methodologically rigorous, reducing the false-positive risk that plagues single-cohort omics studies. That said, all blood sampling was cross-sectional at baseline, so causal directionality between UPF-induced metabolite shifts and cardiovascular events cannot be fully established; residual confounding from dietary measurement error via food frequency questionnaires also remains a limitation. Still, by naming specific circulating metabolites as candidate mediators, this research opens a practical path toward mechanistic validation, potential biomarker panels for cardiovascular risk stratification, and ultimately drug or dietary targets. For the longevity-focused reader, it shifts the UPF conversation from "we know it's bad" to "here is the molecular evidence of why."
